Library-based antibody discovery enables quick screening of huge antibody repertoires without traditional immunisation hurdles
Library-based antibody discovery is cutting through pipeline bottlenecks by enabling quick screening of massive, sometimes billions, antibody repertoires, while avoiding traditional immunisation hurdles.
Demand is rising, and global on-demand service providers are few and far between, but library-based antibody discovery is helping push the next generation of therapeutic breakthroughs.
Craft and scale
Library-based immunisation used combinatorial antibody libraries like scFc, Fab, or single-domain (VHH) formats to imitate the immune system's natural diversity in a test tube.
A scientist from Creative Biolabs said: Biocompare's 2024 guide underscores that synthetic or naïve libraries bypass immunisation, crank up diversity, and let teams zero in on rare, high-quality hits with precision."
Creaimmunisation brings more than just libraries, providing premade, ready-to-go collections that have been tested and optimised. Their binder-discovery suite covers diverse antibody platforms, including scFv, Fab, and VHH formats, with engineered depth and refined screening workflows to speed up timelines and increase success rates.
The single-domain VHH library screening services specialise in small, stable and modular molecules that can fit into hard-to-reach epitopes, playing well in challenging therapeutic scenarios.
Differing from traditional CROs, Creative Biolabs can customise antigen production to prime the targets of interest for further screening and to accept targets provided by clients in the form of whole cells/tissues, peptides/haptens, recombinant proteins, membrane proteins, or other in vivo targets by different screening strategies on a case-by-case basis:
Their single-domain (VHH) library screening services specialise in small, stable, and modular molecules that zip into hard-to-reach epitopes and often play well in challenging therapeutic contexts. Different from traditional CROs, Creative Biolabs can customise antigen production to prepare the targets of interest for further screening and also accept targets provided by clients in the form of whole cells/tissues, peptides/haptens, recombinant proteins, membrane proteins, or other in vivo targets by different screening strategies on a case-by-case basis:
- Solid-phase screening
- Solution-sorting screening
- Cell-based screening
- In vivo screening
- Ex vivo screening
Taken even further with the specialised libraries like CaVHH-L4 and HuVHH-S1, which are custom-tuned collections that deliver enhanced diversity and higher hit rates against challenging targets. The libraries aren't 'one-size-fits-all', but rather as kaleidoscopes built for mission-critical antibody discovery.
Screening for specific sdAbs against target protein
Creative Biolabs, in a recent project, used an in-solution screening strategy that combines pre-counter selection with control antibody C1 and positive selection for target protein T1 to identify high-affinity sdAbs, after rounds of screening and ELISA validation of 92 phage clones, three candidates with specific binding to T1 were identified.
Opportunity for students
As researchers tackle increasingly complex targets, ranging from immune checkpoints to GPCRs to neurodegeneration biomarkers, the ability to extract functional molecules from massive libraries has become non-negotiable.
The Creative Biolabs 2025 scholarship program is now open for the next generation of scientists around the world in biology, biopharma, biotechnology, and biochemistry.
Previous winners have proceeded to contribute to cutting-edge research across academia and industry.
